Equities analysts forecast that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will report earnings of ($0.03) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.19) and the highest estimate coming in at $0.26. The company is expected to issue its next earnings results on Thursday, November 1st.
On average, analysts expect that Adaptimmune Therapeutics will report full year earnings of ($1.02) per share for the current fiscal year, with EPS estimates ranging from ($1.27) to ($0.68). For the next year, analysts anticipate that the business will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.56) to ($1.02). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Adaptimmune Therapeutics.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%.
In other news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $13.79, for a total value of $344,750.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ali Behbahani bought 12,000,000 shares of Adaptimmune Therapeutics stock in a transaction dated Friday, September 7th. The stock was acquired at an average cost of $1.67 per share, for a total transaction of $20,040,000.00. The disclosure for this purchase can be found here. 26.47% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $122,000. BB&T Securities LLC purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $128,000. Raymond James Financial Services Advisors Inc. grew its position in Adaptimmune Therapeutics by 70.0% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 13,151 shares during the last quarter. Jane Street Group LLC purchased a new stake in Adaptimmune Therapeutics during the 1st quarter valued at about $168,000. Finally, Trexquant Investment LP purchased a new stake in Adaptimmune Therapeutics during the 2nd quarter valued at about $178,000. 59.32% of the stock is currently owned by institutional investors.
Shares of Adaptimmune Therapeutics stock opened at $10.88 on Tuesday. Adaptimmune Therapeutics has a 12-month low of $6.60 and a 12-month high of $14.63.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.